Interferon-γ and Tumor Necrosis Factor-α Produced by T Cells Reduce the HBV Persistence Form, cccDNA, Without Cytolysis.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Gastroenterology

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1053/j.gastro.2015.09.026PMID 26416327
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis

  2015cited by this paper
• Cellular inhibitor of apoptosis proteins prevent clearance of hepatitis B virus

  2015cited by this paper
• Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA

  2014influential reference
• Alpha-Interferon Suppresses Hepadnavirus Transcription by Altering Epigenetic Modification of cccDNA Minichromosomes

  2013cited by this paper
• Base excision repair.

  2013cited by this paper
• T cells expressing a chimeric antigen receptor that binds hepatitis B virus envelope proteins control virus replication in mice.

  2013cited by this paper
• Serum cytokine profile in patients with hepatitis B e antigen-negative chronic active hepatitis B and inactive hepatitis B virus carriers.

  2013cited by this paper
• TNF-induced target cell killing by CTL activated through cross-presentation.

  2012cited by this paper
• The tumour necrosis factor‐α‐238A allele increases the risk of chronic HBV infection in European populations

  2012cited by this paper
• Living in the liver: hepatic infections

  2012influential reference
• Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection.

  2011cited by this paper
• Interferons Accelerate Decay of Replication-Competent Nucleocapsids of Hepatitis B Virus

  2010cited by this paper
• Persistence of the hepatitis B virus covalently closed circular DNA in HepaRG human hepatocyte-like cells.

  2009cited by this paper
• CD8+ T Cell Control of Hepatitis B Virus Replication: Direct Comparison between Cytolytic and Noncytolytic Functions

  2009cited by this paper
• T cells redirected against hepatitis B virus surface proteins eliminate infected hepatocytes.

  2008cited by this paper
• Induction of Antiviral Cytidine Deaminases Does Not Explain the Inhibition of Hepatitis B Virus Replication by Interferons

  2007cited by this paper
• Interferon‐inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication

  2006cited by this paper
• Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.

  2006cited by this paper
• Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection

  2006cited by this paper
• [Base excision repair].

  2005cited by this paper
• Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids.

  2005cited by this paper
• Association of the −183 polymorphism in the IFN‐γ gene promoter with hepatitis B virus infection in the Chinese population

  2005cited by this paper
• Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo.

  2005cited by this paper
• Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees

  2004influential reference
• Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany

  2004cited by this paper
• Association of TNF-α promoter polymorphisms with the clearance of hepatitis B virus infection

  2003cited by this paper
• Tumor necrosis factor alpha inhibition of hepatitis B virus replication involves disruption of capsid Integrity through activation of NF-kappaB.

  2003cited by this paper
• INAUGURAL ARTICLES: Hepatocyte turnover during resolution of a transient hepadnaviral infection

  2003cited by this paper
• Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection.

  2003cited by this paper
• Pre-S1 Antigen-Dependent Infection of Tupaia Hepatocyte Cultures with Human Hepatitis B Virus

  2003cited by this paper
• Tumor Necrosis Factor Alpha Inhibition of Hepatitis B Virus Replication Involves Disruption of Capsid Integrity through Activation of NF-κB

  2003cited by this paper
• CD8+ T Cells Mediate Viral Clearance and Disease Pathogenesis during Acute Hepatitis B Virus Infection

  2003cited by this paper
• Cytokine Gene Polymorphisms in Patients Infected With Hepatitis B Virus

  2003cited by this paper
• Cytokine-Sensitive Replication of Hepatitis B Virus in Immortalized Mouse Hepatocyte Cultures

  2002cited by this paper
• Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells.

  2000cited by this paper
• Relative Sensitivity of Hepatitis B Virus and Other Hepatotropic Viruses to the Antiviral Effects of Cytokines

  2000cited by this paper
• Viral clearance without destruction of infected cells during acute HBV infection.

  1999influential reference
• Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice.

  1994cited by this paper
• Late phase inhibition of murine cytomegalovirus replication by synergistic action of interferon-gamma and tumour necrosis factor.

  1994cited by this paper
• Human gamma interferon and tumor necrosis factor exert a synergistic blockade on the replication of herpes simplex virus

  1989cited by this paper

• Advances in pharmacological interventions for hepatic fibrosis: from pathogenic mechanisms to novel therapeutic targets

  2026cites this paper
• Characterization and priming of equine muscle-derived mesenchymal stem cells to enhance their anti-inflammatory and immunomodulatory profiles

  2026cites this paper
• APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer

  2025cites this paper
• Chimeric Antigen Receptor (CAR) T-cell Therapy: Engineering Immune Cells To Treat Liver Diseases.

  2025cites this paper
• HBV cccDNA: The Molecular Reservoir of Hepatitis B Persistence and Challenges to Achieve Viral Eradication

  2025cites this paper
• Rapid whole-blood immune profiling reveals heterogeneous HBV-specific T cell response patterns independent of clinical disease phases.

  2025cites this paper
• Functional cure of chronic hepatitis B virus infection: current therapeutic regimens

  2025cites this paper
• Immunomodulatory effect of Moringa oleifera and Phyllanthus niruri extracts on anti-HBV cytokine production by human peripheral blood mononuclear cells

  2025cites this paper
• Role of Immune Cells in Hepatitis B Virus and Associated Sequelae.

  2025cites this paper
• Biology of Hepatitis B Virus DNA integration and its impact on antiviral R&D.

  2025cites this paper
• Targeting HBV cccDNA through chromatin destabilization: A new frontier in antiviral therapy

  2025cites this paper
• Current status of drug therapy for chronic hepatitis B

  2025cites this paper
• D-Cycloserine, a potential candidate for reducing hepatitis B virus cccDNA in vitro.

  2025cites this paper
• Targeting HBV with RNA interference: Paths to cure.

  2025cites this paper
• Stem cell activity shapes the pleiotropic effects of IFN-γ and TGF-β in autoimmune diseases, infections, and cancer, and drives autoimmune flares and remissions

  2025cites this paper
• Infection Risk in Biological Disease-Modifying Anti-rheumatic Drugs

  2025cites this paper
• mRNA vaccines for HBV: Mechanisms, preclinical advances, and therapeutic clinical progress

  2025cites this paper
• Intrahepatic CD161hiCD8+T Cell Recruitment Has a Pathogenetic Potential in Chronic HBV Infection

  2025cites this paper
• An immune-based predictive model for HBV clearance: validation in multicenter cohorts and mechanistic insights from in vivo studies

  2025cites this paper
• Targeting HBV cccDNA Levels: Key to Achieving Complete Cure of Chronic Hepatitis B

  2024cites this paper
• Optimization of culture conditions for HBV-specific T cell expansion in vitro from chronically infected patients

  2024cites this paper
• Mechanisms underlying the compromised clinical efficacy of interferon in clearing HBV

  2024cites this paper
• Molecular epidemiology of hepatitis B virus (HBV) in Ethiopia: A review article.

  2024cites this paper
• cccDNA epigenetic regulator as target for therapeutical vaccine development against hepatitis B.

  2024cites this paper
• Design of multi-epitope-based therapeutic vaccine candidates from HBc and HBx proteins of hepatitis B virus using reverse vaccinology and immunoinformatics approaches

  2024cites this paper
• Activating adaptive immunity by bispecific, T-cell engager antibodies bridging infected and immune-effector cells is a promising novel therapy for chronic hepatitis B.

  2024cites this paper
• Priming and Maintenance of Adaptive Immunity in the Liver.

  2024cites this paper
• Cytokines profile in occult hepatitis B virus infections in blood donors at the National Blood Transfusion Center of Lomé, Togo

  2024cites this paper
• Association between autoimmune liver diseases and chronic hepatitis B: A multivariable Mendelian randomization study in European population.

  2024cites this paper
• Hepatitis B virus-induced cirrhosis: Mechanisms, global variations, and treatment advances

  2024cites this paper
• A Dual‐domain Engineered Antibody for Efficient HBV Suppression and Immune Responses Restoration

  2024cites this paper
• Polysaccharide of Atractylodes macrocephala Koidz alleviates LPS‐induced proliferation, differentiation inhibition and excessive apoptosis in chicken embryonic myogenic cells

  2024cites this paper
• Elimination of the hepatitis B virus: A goal, a challenge

  2024cites this paper
• Tackling hepatitis B Virus with CRISPR/Cas9: advances, challenges, and delivery strategies

  2024cites this paper
• Intracellular Host Restriction of Hepatitis B Virus Replication

  2024cites this paper
• Early application of IFNγ mediated the persistence of HBV in an HBV mouse model.

  2024cites this paper
• Unraveling Macrophage Polarization: Functions, Mechanisms, and “Double-Edged Sword” Roles in Host Antiviral Immune Responses

  2024cites this paper
• Drug exposure characteristics and related pregnancy outcomes in pregnant women: an observational cohort study.

  2024cites this paper
• Leveraging oncovirus-derived antigen against the viral malignancies in adoptive cell therapies

  2024cites this paper
• Dysfunction and regulatory interplay of T and B cells in chronic hepatitis B: immunotherapy and emerging antiviral strategies

  2024cites this paper
• Antiviral Therapy of Chronic Hepatitis B Virus between Present and Future

  2024cites this paper
• An allosteric inhibitor of sirtuin 2 blocks hepatitis B virus covalently closed circular DNA establishment and its transcriptional activity.

  2024cites this paper
• Functional B cell deficiency promotes intrahepatic HBV replication and impairs the development of anti-HBV T cell responses

  2024cites this paper
• Stem Cell-Derived Hepatocyte-Like Cells for Hepatitis B Virus Infection.

  2024cites this paper
• Epigenetic regulation and its therapeutic potential in hepatitis B virus covalently closed circular DNA

  2024cites this paper
• Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy.

  2023cites this paper
• APOBEC3 activity promotes the survival and evolution of drug-tolerant persister cells during acquired resistance to EGFR inhibitors in lung cancer

  2023cites this paper
• A small molecule iCDM-34 identified by in silico screening suppresses HBV DNA through activation of aryl hydrocarbon receptor

  2023cites this paper
• Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy.

  2023cites this paper
• Cytokines Expression Compared to the Determinants of Cellular Apoptosis Prominently Attributes to the Deleterious Effects of ‘A’ Determinant Surface Gene Mutations in HBV Transfected Hepatoma Cell Line

  2023cites this paper
• Comparative effectiveness of tenofovir versus entecavir in patients with hepatitis B virus-related cirrhosis in Taiwan: a retrospective cohort study

  2023cites this paper
• Activation of AIM2 by hepatitis B virus results in antiviral immunity that suppresses hepatitis C virus during coinfection

  2023cites this paper
• Hepatitis B surface antigen reduction is associated with hepatitis B core-specific CD8+ T cell quality

  2023cites this paper
• Immune response and treatment targets of chronic hepatitis B virus infection: innate and adaptive immunity

  2023cites this paper
• Seneca Valley virus induces proinflammatory cytokine and chemokine response in vitro.

  2023cites this paper
• Development of Polyvinyl Alcohol/Polyethylene Glycol Copolymer-based Orodispersible Films Loaded with Entecavir: Formulation and In vitro Characterization.

  2023cites this paper
• Transient and tunable CRISPRa regulation of APOBEC/AID genes for targeting hepatitis B virus

  2023cites this paper
• Therapies against chronic hepatitis B infections: The times they are a-changin', but the changing is slow!

  2023cites this paper
• IL2-inducible T-cell Kinase is Required for HBV-induced Type T Interferon Expression and Antiviral Response

  2023cites this paper
• A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression

  2023cites this paper
• Current Status and Challenges in Anti-Hepatitis B Virus Agents Based on Inactivation/Inhibition or Elimination of Hepatitis B Virus Covalently Closed Circular DNA

  2023cites this paper
• Dynamics of Hepatitis B Virus Covalently Closed Circular DNA: A Mini-Review

  2023cites this paper
• IFN-γ: A Crucial Player in the Fight Against HBV Infection?

  2023influential citation
• Novel therapeutic strategies for chronic hepatitis B

  2022cites this paper
• Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse

  2022cites this paper
• Analyzing the gene regulatory network in hepatitis B patients by single-cell ATAC sequencing

  2022cites this paper
• Non-cytotoxic functions of CD8 T cells: “repentance of a serial killer”

  2022cites this paper
• Hepatitis B Virus Core Protein Is Not Required for Covalently Closed Circular DNA Transcriptional Regulation

  2022cites this paper
• Robust antiviral responses in severe hepatitis flare persist after early retreatment cessation and lead toward hepatitis B surface antigen loss: A proof‐of‐concept study

  2022cites this paper
• Activities of endogenous APOBEC3s and uracil-DNA-glycosylase affect the hypermutation frequency of hepatitis B virus cccDNA.

  2022cites this paper
• Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins

  2022cites this paper
• Innate and Adaptive Immunopathogeneses in Viral Hepatitis; Crucial Determinants of Hepatocellular Carcinoma

  2022cites this paper
• Natural antibody IgG levels are associated with HBeAg-positivity and seroconversion in chronic hepatitis B patients treated with entecavir

  2022cites this paper
• Interaction between the Hepatitis B Virus and Cellular FLIP Variants in Viral Replication and the Innate Immune System

  2022cites this paper
• Model to predict on‐treatment restoration of functional HBV‐specific CD8 + cell response foresees off‐treatment HBV control in eAg‐negative chronic hepatitis B

  2022cites this paper
• Follow-Up of 108 Patients with Chronic Hepatitis B Virus Infection Treated with Polyethylene Glycol-Conjugated Derivatives of Interferon-Alpha and Monitoring of Off-Treatment Virological Relapse

  2022cites this paper
• Alpha‐kinase 1 (ALPK1) agonist DF‐006 demonstrates potent efficacy in mouse and primary human hepatocyte (PHH) models of hepatitis B

  2022cites this paper
• Hepatitis B Flare in Hepatitis B e Antigen-Negative Patients: A Complicated Cascade of Innate and Adaptive Immune Responses

  2022cites this paper
• Getting to HBV cure: The promising paths forward

  2022cites this paper
• Discovery of a first-in-class orally available HBV cccDNA inhibitor.

  2022cites this paper
• State-of-the-art and emerging antivirals for chronic hepatitis B infection

  2022cites this paper
• Bayesian analysis of cytokines and chemokine identifies immune pathways of HBsAg loss during chronic hepatitis B treatment

  2021cites this paper
• Relationships between IL-1β, TNF-α genetic polymorphisms and HBV infection: A meta-analytical study.

  2021cites this paper
• Potential capacity of interferon-α to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus

  2021cites this paper
• Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B

  2021cites this paper
• The Characteristics of Natural Killer Cells and T Cells Vary With the Natural History of Chronic Hepatitis B in Children

  2021cites this paper
• HBV covalently closed circular DNA minichromosomes in distinct epigenetic transcriptional states differ in their vulnerability to damage

  2021cites this paper
• Regulatory function of interferon‐inducible 44‐like for hepatitis B virus covalently closed circular DNA in primary human hepatocytes

  2021cites this paper
• Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B

  2021cites this paper
• JNJ-64794964 (AL-034/TQ-A3334), a TLR7 agonist, induces sustained anti-HBV activity in AAV/HBV mice via non-cytolytic mechanisms.

  2021cites this paper
• Suppression of hepatitis B virus through therapeutic activation of RIG-I and IRF3 signaling in hepatocytes

  2021cites this paper
• Characterization of a library of 20 HBV-specific MHC class II-restricted T cell receptors

  2021cites this paper
• A Novel Mouse Model Harboring Hepatitis B Virus Covalently Closed Circular DNA

  2021cites this paper
• Concentration of Na+-taurocholate-cotransporting polypeptide expressed after in vitro-transcribed mRNA transfection determines susceptibility of hepatoma cells for hepatitis B virus

  2021cites this paper
• Interplay Between Non-Canonical NF-κB Signaling and Hepatitis B Virus Infection

  2021cites this paper
• Control of APOBEC3B induction and cccDNA decay by NF-κB and miR-138-5p

  2021cites this paper
• Cytokines profile in patients with acute and chronic hepatitis B infection

  2021cites this paper
• Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection

  2021cites this paper
• Immunogenicity and Antiviral Response of Therapeutic Hepatitis B Vaccination in a Mouse Model of HBeAg-Negative, Persistent HBV Infection

  2021cites this paper
• Rapid and Robust Continuous Purification of High-Titer Hepatitis B Virus for In Vitro and In Vivo Applications

  2021cites this paper